Our findings strongly suggest that the consideration of the cell’s intrinsic circadian rhythm and the selection of a specific time point in the TMZ/TP53 systems’ delivery approach may enhance the systems’ cellular targeting, uptake and, ultimately, therapeutic precision in glioblastoma treatment. Here, TP53 is linked to glioblastoma.